Efficient synthetic inhibitors of anthrax lethal factor
- Martino Forino*,†,
- Sherida Johnson*,†,
- Thiang Y. Wong*,
- Dmitri V. Rozanov*,
- Alexei Y. Savinov*,
- Wei Li*,
- Roberto Fattorusso*,
- Barbara Becattini*,
- Andrew J. Orry‡,
- Dawoon Jung*,
- Ruben A. Abagyan‡,
- Jeffrey W. Smith*,
- Ken Alibek§,¶,
- Robert C. Liddington*,
- Alex Y. Strongin*, and
- Maurizio Pellecchia*,∥
- *Burnham Institute, Cancer Research Center and Infectious and Inflammatory Disease Center, 10901 North Torrey Pines Road, La Jolla, CA 92037;‡The Scripps Research Institute, Molecular Biology, 10550 North Torrey Pines Road, La Jolla, CA 92037; §National Center for Biodefense, George Mason University, 10900 University Boulevard, PWII Building, Room 160, MSN 1A8, Manassas, VA 20110; and ¶Advanced Biosystems, 5904 Richmond Highway, Suite 300, Alexandria, VA 22303
-
Edited by Peter K. Vogt, The Scripps Research Institute, La Jolla, CA (received for review April 3, 2005)
-
Fig. 1.
Inhibition of anthrax LF. (a) 19F NMR spectra of the peptide substrate in presence of LF. (b) Effect of GM6001 (20 μM). (c) Effect of BI MFM3 (20 μM). (d) Effect of BI-11B3 (0.8 μM). (e)IC50 evaluation for compound BI-MFM3;(f) Lineweaver–Burk K m and K m(app) evaluation for LF, BI-MFM3, and BI-11B3, respectively. Each measurement was performed in triplicate. (g) Synthetic scheme adopted for the synthesis of compounds listed in Table 2.
-
Fig. 2.
In vitro and cell-based evaluation. (a) BI-11B2 efficiently protects the purified MAPKK-1 against LF cleavage in vitro. BI-11B2 and GM6001 (as control) were each coincubated with LF and MAPKK1. The digest samples were analyzed by SDS/PAGE to determine the specific conversion of MAPKK1 into the 45-kDa cleavage product. (b) Inhibitors BI-11B2 and BI-11B3 are effective in protecting MAPKK1 and murine macrophage RAW264.7 cells against LF. Cells were coincubated with anthrax PA (500 ng/ml) and LF (40 ng/ml). The indicated concentrations of the inhibitors were added to the cells. In 4 h, the residual viable cells were measured by adding the tetrazolium salt 3,[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT). The data show that inhibitors BI-11B2 (open circles) and BI-11B3 (filled circles) protect cells from the cytotoxic effect by LF and PA.
-
Fig. 3.
Crystal structure of the LF-BI-MFM3–zinc complex. (a) Detailed view of the electron density trace and overall model fit of BI-MFM3.(b) Detail of the binding site of LF for MFM3 (both shown in stick representation). These data are at a resolution limit of 2.67 Å. The small molecule appears to be interacting with the zinc atom in the LF active site via an S atom. Additional interactions are mainly of hydrophobic nature involving the aromatic rings of the inhibitor and hydrophobic side chains of LF. Prepared by using spock (http://quorum.tamu.edu/spock) and sybyl (Tripos Associates, St. Louis).
-
Fig. 4.
Comparison of survival rates between different treatments regimes. DBA2 mice were infected with B. anthracis Sterne spores at a dosage of 2 × 107 per mouse in 200 μl of PBS on day 0 through i.p. injection. Animals were treated with ciprofloxacin alone or in combination with lethal toxin blocking substance B1-11B3. Similar data were obtained with compound BI-11B1 (not shown). Treatment was started 24 h postexposure and continued for 10 days. Nontreated mice were used as a control. Animals were monitored for 14 days after infection.
Footnotes
- Copyright © 2005, The National Academy of Sciences









